Farallon Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Farallon Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$676K	Hold	4,000	–	–	﹤0.01%	104
2025 Q4	$731K	Hold	4,000	–	–	﹤0.01%	90
2025 Q3	$486K	Hold	4,000	–	–	﹤0.01%	93
2025 Q2	$418K	Hold	4,000	–	–	﹤0.01%	94
2025 Q1	$467K	Hold	4,000	–	–	﹤0.01%	96
2024 Q4	$338K	Hold	4,000	–	–	﹤0.01%	108
2024 Q3	$359K	Hold	4,000	–	–	﹤0.01%	115
2024 Q2	$322K	Hold	4,000	–	–	﹤0.01%	115
2024 Q1	$319K	Hold	4,000	–	–	﹤0.01%	131
2023 Q4	$318K	Sell	4,000 -121,653	-97%	-$8.13M	﹤0.01%	118
2023 Q3	$8.78M	Sell	125,653 -147,147	-54%	-$11M	0.04%	90
2023 Q2	$19.6M	Buy	+272,800	New	+$20.1M	0.1%	79
2020 Q1	–	Sell	-442,222	Closed	-$45.7M	–	105
2019 Q4	$45.7M	Buy	442,222 +42,222	+11%	+$1.71M	0.31%	58
2019 Q3	$8.1M	Buy	+400,000	New	+$10.3M	0.06%	87

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Farallon Capital Management's AXSM Position: Q1 2026 in Review

Farallon Capital Management held its Axsome Therapeutics (AXSM) position steady in Q1 2026 at 4,000 shares worth $676K. The position accounts for ﹤0.01% of the portfolio, ranked #104.

Farallon Capital Management first reported a position in AXSM in Q3 2019 and has held it in 14 quarters since. The position peaked at $45.7M in Q4 2019. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Farallon Capital Management held 4,000 shares of Axsome Therapeutics worth $676K as of Q1 2026.
Farallon Capital Management left its Axsome Therapeutics share count unchanged in Q1 2026.
Axsome Therapeutics made up ﹤0.01% of Farallon Capital Management's portfolio in Q1 2026, its #104 holding.
Farallon Capital Management first reported a position in Axsome Therapeutics in Q3 2019 and has held it in 14 quarters since.
Farallon Capital Management's Axsome Therapeutics position peaked at $45.7M in Q4 2019.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.